Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Medical Genetics
Published in: BMC Medical Genetics 1/2018

Open Access 01-12-2018 | Research article

Identification of a novel GNAS mutation in a case of pseudohypoparathyroidism type 1A with normocalcemia

Authors: Xiao-dan Long, Jing Xiong, Zhao-hui Mo, Chang-sheng Dong, Ping Jin

Published in: BMC Medical Genetics | Issue 1/2018

Login to get access

Abstract

Background

Pseudohypoparathyroidism type 1A (PHP1A) is a rare genetic disease primarily characterized by resistance to parathyroid hormone along with hormonal resistance and other features of Albright hereditary osteodystrophy (AHO). It is caused by heterozygous inactivating mutations in the maternal allele of the GNAS gene, which encodes the stimulatory G-protein alpha subunit (Gsα) and regulates production of the second messenger cyclic AMP (cAMP). Herein, we report a case of of PHP1A with atypical clinical manifestations (oligomenorrhea, subclinical hypothyroidism, and normocalcemia) and explore the underlying genetic cause in this patient.

Methods

Blood samples were collected from the patient, her family members, and 100 healthy controls. The 13 exons and flanking splice sites of the GNAS gene were amplified by PCR and sequenced. To further assess whether the novel mutation resulted in gain or loss of function of Gsα, we examined the level of cAMP activity associated with this mutation through in vitro functional studies by introducing the target mutation into a human GNAS plasmid.

Results

A novel heterozygous c.715A > G (p.N239D) mutation in exon 9 of the GNAS gene was identified in the patient. This mutation was also found in her mother, who was diagnosed with pseudopseudohypoparathyroidism. An in vitro cAMP assay showed a significant decrease in PTH-induced cAMP production in cells transfected with the mutant plasmid, compared to that in the wild-type control cells (P < 0.01), which was consistent with loss of Gsa activity.

Conclusion

We identified a novel GNAS mutation that altered Gsα function, which furthers our understanding of the pathogenesis of this disease. Screening for GNAS mutations should be considered in suspected cases of PHP1A even if the classical signs are not present.
Appendix
Available only for authorised users
Literature
1.
Mantovani G. Clinical review: Pseudohypoparathyroidism: diagnosis and treatment. J Clin Endocrinol Metab. 2011;96(10):3020–30.CrossRefPubMed
2.
Nakamura Y, Matsumoto T, Tamakoshi A, et al. Prevalence of idiopathic hypoparathyroidism and pseudohy-poparathyroidism in Japan. J Epidemiol. 2000;10(1):29–33.CrossRefPubMed
3.
Underbjerg L, Sikjaer T, Mosekilde L, et al. Pseudohypoparathyroidism - epidemiology, mortality and risk of complications. Clin Endocrinol. 2016;84(6):904–11.CrossRef
4.
de Sanctis L. Pseudohypoparathyroidism: history of the disease. J Pediatr Endocrinol Metab. 2006;19:627–33.PubMed
5.
Farfel Z, Bourne HR, Iiri T. The expanding spectrum of G protein diseases. N Engl J Med. 1999;340(13):1012–20.CrossRefPubMed
6.
Elli FM, Linglart A, Garin I, et al. The prevalence of GNAS deficiency-related diseases in a large cohort of patients characterized by the EuroPHP network. J Clin Endocrinol Metab. 2016;101(10):3657–68.CrossRefPubMed
7.
Lemos MC, Thakker RV. GNAS mutations in Pseudohypoparathyroidism type 1a and related disorders. Hum Mutat. 2015;36(1):11–9.CrossRefPubMed
8.
Wettschureck N, Offermanns S. Mammalian G proteins and their cell type specific functions. Physiol Rev. 2005;85(4):1159–204.CrossRefPubMed
9.
Thiele S, Werner R, Grötzinger J, et al. A positive genotype-phenotype correlation in a large cohort of patients with Pseudohypoparathyroidism type Ia and pseudo-pseudohypoparathyroidism and 33 newly identified mutations in the GNAS gene. Mol Genet Genomic Med. 2015;3(2):111–20.CrossRefPubMed
10.
Iiri T, Herzmark P, Nakamoto JM, et al. Rapid GDP release from Gs alpha in patients with gain and loss of endocrine function. Nature. 1994;371:164–8.CrossRefPubMed
11.
Nakamoto JM, Zimmerman D, Jones EA, et al. Concurrent hormone resistance (pseudohypoparathyroidism type Ia) and hormone independence (testotoxicosis) caused by a unique mutation in the G alpha s gene. Biochem Mol Med. 1996;58:18–24.CrossRefPubMed
12.
Koyama H, Goodpasture C, Miller MM, Teplitz RL, Riggs AD. Establishment and characterization of a cell line from the American opossum (Didelphys virginiana). In Vitro. 1978;14(3):239–46.CrossRefPubMed
13.
Caverzasio J, Rizzoli R, Bonjour JP. Sodium-dependent phosphate transport inhibited by parathyroid hormone and cyclic AMP stimulation in an opossum kidney cell line. J Biol Chem. 1986;261(7):3233–7.PubMed
14.
Teitelbaum AP, Strewler GJ. Parathyroid hormone receptors coupled to cyclic adenosine monophosphate formation in an established renal cell line. Endocrinology. 1984;114(3):980–5.CrossRefPubMed
15.
16.
Tamada Y, Kanda S, Suzuki H, et al. A pseudohypoparathyroidism type Ia patient with normocalcemia. Endocr J. 2008;55(1):169–73.CrossRefPubMed
17.
Ozbey N. Pseudohypoparathyroidism with normocalcemia. J Endocrinol Investig. 2001;24(8):642–3.CrossRef
18.
Thiele S, Werner R, Ahrens W, et al. A disruptive mutation in exon 3 of the GNAS gene with albright hereditary osteodystrophy, normocalcemic pseudohypoparathyroidism, and selective long transcript variant Gsalpha-L deficiency. J Clin Endocrinol Metab. 2007;92(5):1764–8.CrossRefPubMed
19.
Turan S, Thiele S, Tafaj O, et al. Evidence of hormone resistance in a pseudo-pseudohypoparathyroidism patient with a novel paternal mutation in GNAS. Bone. 2015;71:53–7.CrossRefPubMed
20.
Ish-Shalom S, Rao LG, Levine MA, et al. Normal parathyroid hormone responsiveness of bone-derived cells from a patient with pseudohypopar- athyroidism. J Bone Miner Res. 1996;11:8–14.CrossRefPubMed
21.
Pinsker JE, Rogers W, McLean S, et al. Pseudohypoparathyroidism type 1a with congenital hypothyroidism. J Pediatr Endocrinol Metab. 2006;19:1049–52.CrossRefPubMed
22.
Mantovani G, Spada A. Resistance to growth hormone releasing hormone and gonadotropins in Albright’s hereditary osteodystrophy. J Pediatr Endocrinol Metab. 2006;19:663–70.CrossRefPubMed
23.
de Sanctis L, Bellone J, Salerno M, et al. GH secretion in a cohort of children with pseudohypoparathyroidism type Ia. J Endocrinol Investig. 2007;30:97–103.CrossRef
24.
Mantovani G, Maghnie M, Weber G, et al. Growth hormonereleasing hormone resistance in pseudohypoparathyroidism type Ia: new evidence for imprinting of the Gs gene. J Clin Endocrinol Metab. 2003;88:4070–4.CrossRefPubMed
25.
Chaubey SK, Sangla KS. A sporadic case of pseudohypoparathyroidism type 1 and idiopathic primary adrenal insufficiency associated with a novel mutation in the GNAS1 gene. Endocr Pract. 2014;20(10):e202–6.CrossRefPubMed
26.
Kayemba-Kay’s S, Tripon C, Heron A, et al. Pseudohypoparathyroidism type 1A-subclinical hypothyroidism and rapid weight gain as early clinical signs: a clinical review of 10 cases. J Clin Res Pediatr Endocrinol. 2016;8(4):432–8.CrossRefPubMedPubMedCentral
27.
Williams GR, Bassett JHD. Thyroid diseases and bone health. J Endocrinol Investig. 2017;2:1–11.
28.
Kakuno Y, Amino N, Kanoh M, et al. Menstrual disturbances in various thyroid diseases. Endocr J. 2010;57(12):1017–22.CrossRefPubMed
29.
Fernandez-Rebollo E, Lecumberri B, Gaztambide S, et al. Endocrine profile and phenotype-(epi)genotype correlation in Spanish patients with pseudohypoparathyroidism. J Clin Endocrinol Metab. 2013;98:996–1006.CrossRef
30.
Weinstein LS, Yu S, Warner DR, et al. Endocrine manifestations of stimulatory G protein alpha-subunit mutations and the role of genomic imprinting. Endocr Rev. 2001;22(5):675–705.PubMed
31.
Tam VH, Chen SP, Mak CM, et al. A novel mutation in pseudohypoparathyroidism type 1a in a Chinese woman and her son with hypocalcaemia. Hong Kong Med J. 2014;20(3):258–60.CrossRefPubMed
32.
Ishikawa Y, Tajima T, Nakae J, et al. Two mutations of the Gsalpha gene in two Japanese patients with sporadic pseudohypoparathyroidism type Ia. J Hum Genet. 2001;46(7):426–30.CrossRefPubMed
33.
Freson K, Izzi B, Jaeken J, et al. Compound heterozygous mutations in the GNAS gene of a boy with morbid obesity, thyroid- stimulating hormone resistance, pseudohypoparathyroidism, and a prothrombotic state. J Clin Endocrinol Metab. 2008;93(12):4844–9.CrossRefPubMed
34.
Ngai YF, Chijiwa C, Mercimek-Mahmutoglu S, et al. Pseudohypoparathyroidism type 1a and the GNAS p.R231H mutation: somatic mosaicism in a mother with two affected sons. Am J Med Genet A. 2010;152A(11):2784–90.CrossRefPubMed
35.
Shore EM, Ahn J, Jan de Beur S, et al. Paternally inherited inactivating mutations of the GNAS1 gene in progressive osseous heteroplasia. N Engl J Med. 2002;346(2):99–106.CrossRefPubMed
36.
Sunahara RK, Tesmer JJ, Gilman AG, et al. Crystal structure of the adenylyl cyclase activator Gsalpha. Science. 1997;278(5345):1943–7.CrossRefPubMed
37.
Johnston CA, Siderovski DP. Receptor-mediated activation of heterotrimeric G-proteins: current structural insights. Mol Pharmacol. 2007;72(2):219–30.CrossRefPubMed
38.
Johnston CA, Willard FS, Jezyk MR, et al. Structure of Galpha(i1) bound to a GDP-selective peptide provides insight into guanine nucleotide exchange. Structure. 2005;13:1069–80.CrossRefPubMedPubMedCentral
39.
Farfel Z, Iiri T, Shapira H, Roitman A, Mouallem M, Bourne HR. Pseudohypoparathyroidism, a novel mutation in the betagamma-contact region of Gsalpha impairs receptor stimulation. J Biol Chem. 1996;271(33):19653–5.CrossRefPubMed
40.
Metadata
Title
Identification of a novel GNAS mutation in a case of pseudohypoparathyroidism type 1A with normocalcemia
Authors
Xiao-dan Long
Jing Xiong
Zhao-hui Mo
Chang-sheng Dong
Ping Jin
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Medical Genetics / Issue 1/2018
Electronic ISSN: 1471-2350
DOI
https://doi.org/10.1186/s12881-018-0648-z

Other articles of this Issue 1/2018

BMC Medical Genetics 1/2018 Go to the issue

CASE REPORT

A 73,128 bp de novo deletion encompassing the OPN1LW/OPN1MW gene cluster in sporadic Blue Cone Monochromacy: a case report

Case report

Identification of a novel nonsense mutation in SH2D1A in a patient with X-linked lymphoproliferative syndrome type 1: a case report

Case report

Identification of a novel nonsense mutation in the UNC13D gene from a patient with hemophagocytic lymphohistiocytosis: a case report

Research article

Do polymorphisms in protein kinase catalytic subunit alpha-1 gene associated with cancer susceptibility? a meta-analysis and systematic review

Case report

FLNA mutations in surviving males presenting with connective tissue findings: two new case reports and review of the literature

Case report

Two novel L2HGDH mutations identified in a rare Chinese family with L-2-hydroxyglutaric aciduria